We hypothesized that targeting the MEK pathway in combination with selective inhibitors of PI3K/mTOR signaling, could overcome gefitinib-resistant NSCLC and enhance the antitumor efficacy. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.